Phase II Study of Combination Therapy with S-1 and Irinotecan for Advanced Non–Small Cell Lung Cancer: West Japan Thoracic Oncology Group 3505
Isamu Okamoto(Kyushu University Hospital), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Hiroshige Yoshioka(Harbin Medical University), Akihito Kubo(Aichi Medical University), Takashi Nishimura(Hyogo University), Shunichi Sugawara(Sendai Kousei Hospital), Masaki Miyazaki(Suita Municipal Hospital), Nobuyuki Katakami(Takarazuka City Hospital), Koji Takeda(NewYork–Presbyterian Hospital), Masahiro Fukuoka(National Institute of Standards and Technology), Noriyuki Ebi(Aso Iizuka Hospital)
Cited by 26
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k